What Are Insulin Pumps?

Insulin pumps are small, programmable medical devices that deliver insulin continuously to people with diabetes, replacing the multiple daily injections otherwise required to manage blood glucose levels. Rather than administering insulin in discrete manual doses, a pump infuses rapid-acting insulin through a subcutaneous catheter at rates that can be adjusted minute by minute, mimicking the way a healthy pancreas releases basal insulin throughout the day and larger bolus amounts at mealtimes.

The technology emerged in the 1970s with bulky, hospital-grade "artificial pancreas" prototypes and moved to wearable form with the "blue brick" device of 1978. Commercial adoption accelerated after the Diabetes Control and Complications Trial of the early 1990s demonstrated that intensive insulin therapy substantially reduces the long-term vascular complications of type 1 diabetes. By the mid-2000s, insulin pump therapy had become a standard clinical option for patients who require tight glycemic control. The PMC review of insulin pump clinical history traces this progression from early open-loop devices to the sophisticated systems in use today.

Delivery Mechanisms

An insulin pump operates on two distinct delivery modes. Basal delivery runs continuously at a programmed rate, typically measured in units per hour, and can follow a time-of-day schedule to account for predictable physiological patterns such as the dawn phenomenon. Bolus delivery is user-triggered to cover carbohydrate intake or to correct elevated glucose. Most devices allow bolus doses as small as 0.025 units, a precision that syringes and pens cannot reliably match. Insulin is stored in a replaceable reservoir and flows through soft plastic tubing to an infusion set, a small plastic cannula inserted into subcutaneous tissue in the abdomen, thigh, or upper arm. Patch pumps, a tubeless variant, integrate the reservoir and cannula into a single adhesive pod worn directly on the skin, communicating with a handheld controller via radio frequency.

Device Types and Automation

The PMC systematic review of insulin pump advancements classifies current devices into three categories: conventional tethered pumps, patch pumps, and implantable pumps placed surgically within the peritoneal cavity for intraperitoneal delivery. Conventional tethered pumps remain the most widely deployed, while patch pumps have grown in popularity because they eliminate tubing management. The clinical frontier is the hybrid closed-loop system, sometimes called an artificial pancreas. These devices pair the pump with a continuous glucose monitor (CGM) and a control algorithm that adjusts basal delivery automatically every five minutes based on real-time CGM readings. The MiniMed 670G received FDA approval in 2016 as the first commercially available hybrid closed-loop system, and subsequent generations have incorporated increasingly sophisticated predictive algorithms that also adjust pre-meal insulin delivery.

Control Algorithms and Safety Features

The software governing insulin delivery incorporates safety constraints designed to prevent overdosing. A basal insulin suspend function halts delivery when the CGM signals or predicts hypoglycemia, reducing the frequency and severity of low blood glucose events. More advanced systems implement model-predictive control that uses a mathematical model of insulin-glucose dynamics to forecast glucose trajectories and adjust delivery proactively. The ADA and EASD consensus report on automated insulin delivery summarizes clinical evidence showing that fully automated delivery reduces time spent below target glucose ranges while improving time in the target range for most patient populations.

Applications

Insulin pumps have applications in a range of medical and research contexts, including:

• Type 1 diabetes management requiring tight glycemic control
• Type 2 diabetes when oral agents and injections are insufficient
• Pregnancy in patients with preexisting diabetes, where glucose targets are especially strict
• Pediatric diabetes care, where variable activity patterns make fixed injection schedules difficult
• Clinical research into closed-loop control and artificial pancreas algorithms